Shijiazhuang Yiling Pharmaceutical (002603.SZ): The clinical trial application for LB220-D08 extended-release tablets has been approved.

Shijiazhuang Yiling Pharmaceutical (002603.SZ) announced that the company recently received the "Drug Clinical Trial Approval Notice" approved and issued by the National Medical Products Administration, and LB220-D08 extended-release tablets have been approved to conduct clinical trials for atypical hemolytic uremic syndrome (aHUS). It is reported that LB220-D08 is a novel small-molecule chemical drug independently developed by the company and is a Class 1 chemical new drug with independent intellectual property rights. This product is a complement inhibitor targeting Factor B. By targeted inhibition of Factor B, this product can selectively inhibit the alternative pathway, prevent the activation of C3 convertase, thereby inhibiting the generation of toxins such as C3a and C5a as well as the formation of C5 convertase and the membrane attack complex (MAC, C5b-9), while maintaining the normal functions of the lectin and classical pathway signaling pathways.